Document Detail


Infliximab in the treatment of amyloidosis secondary to Crohn’s disease.
MedLine Citation:
PMID:  22592423     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Secondary amyloidosis (AA) is a severe complication of progressed Crohn’s disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.
Authors:
J B Cabezuelo; J Pedro Egea; F Ramos; E Torrella; S Muray; C Alcázar
Related Documents :
8456803 - Non-invasive prenatal diagnosis of osteogenesis imperfecta.
8423613 - Reproductive possibilities for balanced translocation (14) carriers in families with pa...
25294163 - Individual differences in the concordance of self-reports and official records.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia     Volume:  32     ISSN:  1989-2284     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301215     Medline TA:  Nefrologia     Country:  -    
Other Details:
Languages:  ENG; SPA     Pagination:  385-388     Citation Subset:  -    
Vernacular Title:
Utilidad del infliximab en el tratamiento de la amiloidosis secundaria en la enfermedad de Crohn.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for t...
Next Document:  Analysis of concordance between the bioelectrical impedance vector analysis and the bioelectrical im...